Analyst Stephen Brozak of WBB Securities reiterated a Buy rating on Marker Therapeutics (MRKR – Research Report), with a price target of $12.50.
Stephen Brozak has given his Buy rating due to a combination of factors that highlight Marker Therapeutics’ promising position in the immuno-oncology field. The company’s innovative MAR-T cell therapy, which utilizes non-genetically engineered T cells, shows potential in treating both blood cancers and solid tumors. The recent 2024 year-end report underscores Marker Therapeutics’ financial stability and clinical advancements, which are crucial in the current healthcare landscape.
Furthermore, the company has successfully secured over $13 million in non-dilutive funding to advance its lead product, MT-601, in treating metastatic pancreatic cancer and non-Hodgkin’s lymphoma. Encouraging preliminary data from the Phase 1 APOLLO study, with a 78% objective response rate in lymphoma patients, further supports the positive outlook. These developments, along with strategic financial backing from reputable investors, reinforce the confidence in Marker Therapeutics’ future growth and justify the Strong Buy rating.